NAD+ IV Therapy: Evidence, Benefits & What It Costs

NAD+ IV therapy is the most heavily marketed — and most expensive — way to "boost your NAD+." Clinics and mobile-drip services promise an immediate lift in energy, mental clarity, recovery, and even anti-aging, delivered straight into your bloodstream over a few hours. The price tag matches the promise: a single infusion commonly runs several hundred dollars. So it's worth asking the uncomfortable question plainly, before you book one: **what does the human evidence actually show for intravenous NAD+ — and is it worth the cost?**

The honest answer is that the gap between the marketing and the science here is unusually wide. This page lays out what is genuinely known, what is merely assumed, and what an IV drip realistically costs.

What NAD+ IV therapy is

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell. It carries electrons through the reactions that turn food into usable cellular energy, and it also fuels DNA-repair enzymes and the sirtuin proteins. Because it sits at the center of energy metabolism, low NAD+ availability can ripple outward into mitochondrial and metabolic dysfunction ¹. NAD+ also tends to fall with age: a study of human tissue documented age-associated declines in NAD+ alongside rising oxidative stress ². That age-related decline is the entire rationale behind "NAD+ restoration."

IV therapy takes that idea to its most literal extreme. Rather than swallowing a precursor and letting your body convert it, an NAD+ drip delivers NAD+ itself directly into a vein, typically infused slowly over two to six hours because faster rates cause uncomfortable side effects (more on that below). The pitch is intuitive: skip the gut, flood the bloodstream, and you've topped up your tank.

The intuition is where the trouble starts.

The one human IV NAD+ study — and what it really found

There is, remarkably, only one published human study that actually measured what happens to NAD+ in your body during an intravenous infusion. In a 2019 pilot, researchers gave participants a 6-hour IV infusion of NAD+ and tracked the plasma and urine NAD+ metabolome throughout ³. It's a genuinely useful piece of work, and it's the closest thing the field has to evidence — so it's worth being precise about what it did and did not show.

What it showed: NAD+ was largely **not** detectable in the bloodstream until several hours into the infusion. For much of the infusion, the body appeared to be metabolizing the NAD+ before free NAD+ rose measurably in plasma, with the metabolite signature shifting over the six hours ³. In other words, even a long, slow IV doesn't simply "fill up" your blood with NAD+ on contact the way the marketing implies.

What it did **not** show: any clinical benefit. This was a small pilot focused on the metabolome — the biochemical fate of the infused NAD+ — not a trial of energy, cognition, recovery, or aging. It had no placebo arm measuring how people felt or performed. So the single human IV study tells us something about pharmacokinetics and essentially nothing about whether IV NAD+ makes you healthier.

The honest framing: there are no IV NAD+ outcome RCTs

Here is the part the clinic industry tends to skip, stated plainly: **there is no rigorous randomized controlled trial showing that intravenous NAD+ improves energy, focus, recovery, or any aging-related outcome in humans.** The entire credible clinical-trial literature on raising NAD+ is built on **oral precursors** — NMN and nicotinamide riboside (NR) — not on IV NAD+.

And it matters that those oral trials are the evidence base, because they are sobering even on their own terms. Oral NMN reliably raises blood NAD+ in a dose-dependent way and is well tolerated ⁵; a pharmaceutical-grade NMN formulation cleanly increased circulating NAD+ and its metabolome ⁶; and chronic NR elevates NAD+ in healthy older adults ⁷. Oral NR's pharmacokinetics in humans are well characterized — it raises blood NAD+ predictably ⁴. So precursors clearly hit the biochemical target.

But raising the biomarker is not the same as improving health, and that distinction is where NAD+ marketing collapses. When NR augmented the aged human muscle NAD+ metabolome, it did **not** improve muscle bioenergetics or physical performance — the fuel gauge moved, the engine output didn't ⁸. When NR raised blood NAD+ roughly 2.6-fold in older adults with mild cognitive impairment, neurocognitive scores were unchanged ⁹. A systematic review and meta-analysis of NAD+ precursors on metabolic-syndrome parameters found clinical benefits to be limited and inconsistent despite reliably raised NAD+ ¹⁰. If the *oral* precursors — the ones with real trials — struggle to convert higher NAD+ into felt benefits, an IV route with **zero** outcome trials cannot honestly claim to do better. We walk through this evidence in depth in our pillar guide to NAD+ therapy evidence.

The benefits clinics promise vs. what's proven

It's worth lining the two up directly:

- **"Instant energy."** The mechanism (NAD+ fuels ATP production) is real, but human trials of NAD+ precursors do not reliably translate raised NAD+ into more felt energy — and no IV trial has tested this at all. See does NAD+ actually boost energy for the trial-by-trial breakdown. - **"Mental clarity / focus."** The one dedicated cognition trial (oral NR in mild cognitive impairment) raised NAD+ but left cognition unchanged ⁹. There is no IV cognition trial. - **"Anti-aging / cellular rejuvenation."** This rests on the NAD+–sirtuin mechanism and animal data, not human outcomes; no NAD+ precursor has been shown to extend human lifespan or reverse aging, and there is no IV evidence whatsoever. See is NAD+ really anti-aging. - **"Addiction recovery / 'NAD+ for withdrawal.'"** This is a common clinic pitch, but it rests on case series and anecdote, not controlled trials.

The pattern is consistent: where there is any human evidence, it's from oral precursors and it's modest at best; for the IV route specifically, the controlled human evidence is simply absent.

Side effects and safety

The most reliable, well-documented effect of NAD+ IV therapy is, ironically, its side effects during infusion. Infused too quickly, NAD+ commonly causes chest tightness or pressure, flushing, nausea, abdominal cramping, lightheadedness, and a racing or pounding sensation — which is precisely why clinics slow the drip down to several hours ³. These are typically transient and ease when the rate is reduced, but they are real and unpleasant, and they undercut the "effortless wellness" framing.

On longer-term safety, what reassurance exists again comes from the **oral** literature: a dedicated safety trial of high-dose NR (3,000 mg/day) found it generally safe and well tolerated ¹¹, and tolerability has been consistent across the oral NMN and NR trials. But "safe in oral trials" does not automatically transfer to repeated high-dose intravenous administration, which has not been studied for long-term safety. As with any IV procedure, there are also the ordinary risks of intravenous access — infection, vein irritation, and the need for proper clinical oversight.

What NAD+ IV therapy actually costs

This is where the value question gets sharp. NAD+ IV therapy is expensive, and pricing is set entirely by clinics and mobile-drip services — there's no insurance coverage, because it's not an approved treatment for any condition.

Typical real-world pricing in the US looks roughly like this:

- **A single IV NAD+ infusion** commonly runs about **$300–$1,000+**, depending on the dose (often quoted as 250 mg up to 1,000 mg or more) and whether it's in-clinic or a premium mobile/at-home visit. - **Multi-session "loading" protocols** — clinics frequently recommend a series of 4 to 10 infusions — push the total into the **low thousands of dollars**. - **Add-ons** (vitamin/glutathione "cocktails," concierge fees) raise the bill further.

Put bluntly: you can spend several thousand dollars on a course of infusions for which there is no controlled human evidence of benefit. By contrast, oral NMN or NR — the routes that actually have human trials showing they raise NAD+ — cost a small fraction of that per month. That doesn't make the oral precursors a proven path to energy or longevity (they aren't), but it does mean you'd be paying a steep premium for the IV route's *unproven* delivery method, not for better-proven results.

The bottom line

NAD+ IV therapy is a premium-priced intervention whose marketing far outruns its evidence. The single human IV study measured the metabolome of a 6-hour infusion and found NAD+ wasn't even readily detectable in blood for hours ³ — it did not test any health outcome. There are **no** randomized controlled trials showing IV NAD+ improves energy, focus, recovery, or aging. The (modest) human evidence that NAD+ can be raised at all comes from inexpensive **oral** precursors, and even those reliably raise the biomarker without reliably improving how people feel or function ⁸⁹¹⁰. Meanwhile a course of infusions can run into the low thousands of dollars.

If you're drawn to NAD+, the evidence-based move is to understand the whole picture first. Start with our NAD+ therapy evidence pillar, see how the precursors compare in NMN vs NR, and check how the products and providers stack up on our NAD+ rankings hub. Treat IV NAD+ as an expensive, unproven option — not the proven shortcut it's sold as.